Approvals in 2016: The March of the checkpoint inhibitors

Nature Reviews Clinical Oncology

Volumn 14, Issue 3, 2017, Pages 131-132

  Blumenthal, Gideon M ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATEZOLIZUMAB; BENDAMUSTINE; CHECKPOINT KINASE INHIBITOR; CRIZOTINIB; DOCETAXEL; ERLOTINIB; NIVOLUMAB; OSIMERTINIB; PEMBROLIZUMAB; PLATINUM COMPLEX; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; RITUXIMAB; RUCAPARIB; VENETOCLAX; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN;

CANCER CHEMOTHERAPY; CHROMOSOME 17P; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CLASSICAL HODGKIN LYMPHOMA; DIAGNOSTIC KIT; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; GENETIC ANALYZER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; NOTE; OVARY CANCER; OVERALL SURVIVAL; PATIENT SAFETY; PATIENT SELECTION; PHARMACOGENETIC TESTING; PROGRESSION FREE SURVIVAL; TRANSITIONAL CELL CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR SUPPRESSOR GENE; UNITED STATES; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; DRUG EFFECTS; MOLECULARLY TARGETED THERAPY; PROCEDURES; STATISTICS AND NUMERICAL DATA;

ANTINEOPLASTIC AGENTS; B7-H1 ANTIGEN; CELL CYCLE CHECKPOINTS; DRUG APPROVAL; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 85013496342     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2017.15     Document Type: Note

References (10)

1. Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicenter, phase 2 trial. Lancet 387, 1909-1920 (2016).
2. Blumenthal, G. M. & Pazdur, R. Response rate as an approval endpoint in oncology: back to the future. JAMA Oncol. 2, 780-781 (2016).
3. Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823-1833 (2016).
4. Ferris, R. L. et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 375, 1856-1867 (2016).
5. Roberts, A. W. et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 374, 311-322 (2016).
6. Kazandjian, D. et al. Benefit-risk summary of crizotinib for the treatment of patients with ROS1 alteration-positive, metastatic non-small cell lung cancer. Oncologist 21, 974-980 (2016).
7. Blumenthal, G. M., Mansfield, E. & Pazdur, R. Next-generation sequencing in oncology in the era of precision medicine. JAMA Oncol. 2, 13-14 (2016).
8. Sherman, R. E. et al. Real-world evidence - what is it and what can it tell us? N. Engl. J. Med. 375, 2293-2297 (2016).
9. National Cancer Institute. Cancer Moonshot Blue Ribbon Panel Report 2016. Cancer.gov https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/blue-ribbon-panel (2016).
10. Pazdur, R. Leveraging the power of collaboration - FDA's new Oncology Center of Excellence. FDA Voice blog http://blogs.fda.gov/ fdavoice/index.php/2016/06/leveraging-the-power-of-collaboration-fdas-new-oncology-center-of-excellence/ (2016).